PGCM
ANIK icon

Prescott Group Capital Management’s Anika Therapeutics ANIK Stock Holding History

Prescott Group Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,000
Closed -$232K – 200
2014
Q2 		$232K Hold
5,000
– – 0.04% 198
2014
Q1 		$205K Buy
+5,000
New +$186K 0.04% 199

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Prescott Group Capital Management's ANIK Position: Q3 2014 in Review

Prescott Group Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 5,000 shares — an estimated $232K sold.

Prescott Group Capital Management first reported a position in ANIK in Q1 2014 and held it in 2 quarters. The position peaked at $232K in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • Prescott Group Capital Management reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Prescott Group Capital Management sold 5,000 Anika Therapeutics shares in Q3 2014, an estimated $232K.
  • Prescott Group Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 2 quarters.
  • Prescott Group Capital Management's Anika Therapeutics position peaked at $232K in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Prescott Group Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.